Welcome to our dedicated page for Invivyd news (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd stock.
Invivyd, Inc. (Nasdaq: IVVD) is a clinical-stage biopharmaceutical company pioneering monoclonal antibody (mAb) therapies to combat evolving viral threats like COVID-19. This page provides investors and stakeholders with timely updates on Invivyd’s regulatory milestones, clinical trial progress, and strategic initiatives.
Discover the latest developments for PEMGARDA™, Invivyd’s EUA-authorized pre-exposure prophylaxis, and next-generation candidates like VYD2311. Our news collection covers critical updates including FDA communications, partnership announcements, and peer-reviewed data publications. All content is vetted for accuracy and relevance to ensure you stay informed on Invivyd’s progress in protecting immunocompromised populations.
Key focus areas include advancements from the proprietary INVYMAB™ platform, trial results demonstrating variant resistance, and manufacturing scalability updates. Bookmark this page for direct access to press releases, earnings call summaries, and analyses of Invivyd’s role in infectious disease innovation.
Invivyd, Inc. (Nasdaq: IVVD) announced a conference call scheduled for March 23, 2023, at 4:30 p.m. ET. The call will discuss its financial results for the year ended December 31, 2022, alongside recent business highlights. Invivyd is focused on developing antibody-based therapies targeting serious viral threats, notably SARS-CoV-2. The company employs advanced techniques in evolutionary virology and antibody engineering to create long-lasting antibodies to counteract viral escape. Investors and analysts can register for the call and access a replay via the company's investor website.
Invivyd, Inc. (Nasdaq: IVVD) announced the election of its monoclonal antibody candidate VYD222 for clinical advancement as a therapeutic option for COVID-19, particularly targeting immunocompromised individuals. The company aims to leverage emerging global regulatory frameworks to expedite development. Currently, no monoclonal antibodies are authorized in the U.S. for COVID-19 prevention or treatment. VYD222, engineered from the investigational adintrevimab, has shown in vitro neutralizing activity against dominant variants, including XBB.1.5. A Phase 1 clinical trial is planned for Q1 2023.
On February 28, 2023, Invivyd, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker IVVD, announced that CEO David Hering will present at Cowen's 43rd Annual Healthcare Conference on March 6, 2023, at 2:10 p.m. ET. The presentation will be available as a live webcast and archived for 90 days on the company’s investor website. Invivyd focuses on combating viral respiratory diseases through innovative antibody development, particularly targeting COVID-19. The company aims to enhance natural immunity to provide superior viral protection.
Invivyd, Inc. (Nasdaq: IVVD) announced the departure of its Chief Scientific Officer, Laura Walker, Ph.D., who is leaving to pursue other opportunities. Lukas Dillinger, Ph.D., has been appointed interim Head of Discovery and Pre-Clinical during the search for a replacement. CEO David Hering expressed gratitude for Walker's contributions, which were essential in establishing the company's pipeline of antibody candidates against SARS-CoV-2. Invivyd focuses on developing antibodies for serious infectious diseases, particularly COVID-19, with ongoing efforts to advance its pipeline of antibody therapies.
Invivyd, Inc. (Nasdaq: IVVD) participated in an FDA-EMA workshop on December 15, 2022, focusing on SARS-CoV-2 monoclonal antibodies. The company's chief scientific officer, Laura Walker, Ph.D., presented alongside industry leaders to discuss strategies for accelerating antibody development amid evolving variants. The presentation underscored the unmet medical need for COVID-19 therapies and proposed data-driven policy changes to optimize development timelines. Invivyd's antibody technologies aim to provide superior protection against viral diseases, including COVID-19.
Invivyd, Inc. (Nasdaq: IVVD) has announced key management changes effective December 16, 2022. Jeremy Gowler has been appointed as the Chief Operating and Commercial Officer, bringing 20 years of biopharma experience, including leadership at Sandoz. Additionally, Pete Schmidt, previously Vice President of Clinical Research, has been promoted to Chief Medical Officer. The company aims to advance its monoclonal antibodies pipeline for COVID-19 and other respiratory diseases while streamlining operations following Dr. Ellie Hershberger's departure, who will provide consulting services.
Invivyd, a clinical-stage biopharmaceutical company (Nasdaq: IVVD), has announced a strategic partnership with Population Health Partners (PHP) aimed at improving the efficiency of its NVD200 clinical program and developing engineered antibodies for COVID-19. This collaboration will leverage PHP's expertise in clinical development and regulatory strategies, aligning Invivyd's capabilities with the evolving SARS-CoV-2 landscape.
Invivyd's NVD200 candidate, integrating adintrevimab, is set to enter clinical trials in Q1 2023, addressing the urgent need for effective treatments amid dwindling antibody effectiveness against emerging variants.
Invivyd (Nasdaq: IVVD) announced its third-quarter 2022 results, highlighting a cash position of $419 million, expected to fund operations into Q2 2024. The company aims to advance its monoclonal antibody candidate, NVD200, into clinical trials in Q1 2023. During the quarter, R&D expenses decreased to $34.1 million from $49.4 million in 2021, while SG&A expenses rose to $13.2 million. The net loss narrowed to $45.1 million from $60.4 million year-over-year, with a per-share loss of $0.42. A conference call is scheduled for November 10 at 4:30 p.m. ET.
Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical firm, announced that CEO David Hering will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15, 2022, at 4:25 p.m. GMT. The event will be accessible via a live webcast on the investor section of Invivyd’s website, with an archive available for 90 days post-presentation.
Invivyd focuses on developing antibodies to enhance immunity against serious viral respiratory diseases, including COVID-19. Its first candidate, NVD200, aims to prevent and treat COVID-19 using advanced antibody technology.
Invivyd, a clinical-stage biopharmaceutical company, announced a conference call to discuss its Q3 financial results on November 10, 2022, at 4:30 p.m. ET. The earnings report will cover the period ending September 30, 2022, alongside recent business highlights. Invivyd focuses on developing antibodies to combat viral respiratory diseases, notably COVID-19, with its candidate NVD200 showing promise. The company aims to enhance immunity against evolving viral threats. Analysts can join the Q&A session after the call.
FAQ
What is the current stock price of Invivyd (IVVD)?
What is the market cap of Invivyd (IVVD)?
